Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase

Vaccine

Volumn 30, Issue 23, 2012, Pages 3413-3422

  Schmeisser, Falko ^a   Adamo, Joan E ^a   Blumberg, Benjamin ^a   Friedman, Rachel ^a   Muller, Jacqueline ^a   Soto, Jackeline ^a   Weir, Jerry P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

H5N1; Influenza immunity; Influenza vaccine; Virus like particle (VLP)

Indexed keywords

HEMAGGLUTININ; MATRIX PROTEIN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SIALIDASE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BACULOVIRUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; ELECTRON MICROSCOPY; EMBRYO; ENZYME ACTIVITY; ERYTHROCYTE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS;

ANIMALS; GENETIC VECTORS; HEMAGGLUTININS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, VIROSOME; VACCINIA VIRUS; VIROSOMES;

EID: 84859836264     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.033     Document Type: Article

References (28)

1. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001, 75(13):6154-6165.
2. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA: NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23(50):5751-5759.
3. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81(7):3514-3524.
4. Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase: but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007, 81(13):7111-7123.
5. Mena I., Vivo A., Perez E., Portela A. Rescue of a synthetic chloramphenicol acetyltransferase RNA into influenza virus-like particles obtained from recombinant plasmids. J Virol 1996, 70(8):5016-5024.
6. Neumann G., Watanabe T., Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J Virol 2000, 74(1):547-551.
7. Wu C.Y., Yeh Y.C., Yang Y.C., Chou C., Liu M.T., Wu H.S., et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010, 5(3):e9784.
8. D'Aoust M.A., Lavoie P.O., Couture M.M., Trépanier S., Guay J.M., Dargis M., et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6(9):930-940.
9. Gomez-Puertas P., Albo C., Perez-Pastrana E., Vivo A., Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000, 74(24):11538-11547.
10. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8(4):435-445.
11. Kang S.M., Song J.M., Quan F.S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res 2009, 143(2):140-146.
12. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(42):5393-5399.
13. Matassov D., Cupo A., Galarza J.M. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 2007, 20(3):441-452.
14. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1):e1501.
15. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009, 27(4):530-541.
16. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238(2):198-211.
17. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89:10847-10851.
18. Earl P.L., Cooper N., Wyatt L.S., Moss B., Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. Current protocols in molecular biology 2003, John Wiley & Sons, Inc., New York, NY. F.M. Ausubel, R. Brent, R.E. Kingston (Eds.).
19. Palmer D.F., Coleman M.T., Dowdle W.R., Schild G.C. Advanced laboratory techniques for influenza diagnosis 1975, U.S. Department of Health, Education and Welfare, Washington, D.C.
20. Schmeisser F., Vodeiko G.M., Lugovtsev V.Y., Stout R.R., Weir J.P. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010, 28(12):2442-2449.
21. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
22. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009, 8(4):447-454.
23. Vasilakis N., Falvey D., Gangolli S.S., Coleman J., Kowalski J., Udem S.A., et al. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors. Nat Biotechnol 2003, 21(8):932-935.
24. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4(3):e4667.
25. Tao P., Luo M., Zhu D., Qu S., Yang Z., Gao M., et al. Virus-like particle vaccine comprised of the HA: NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 2009, 22(4):273-281.
26. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(30):4771-4776.
27. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405(1):165-175.
28. Lai J.C., Chan W.W., Kien F., Nicholls J.M., Peiris J.S., Garcia J.M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol 2010, 91(Pt 9):2322-2330.